Skip to content
Back to meeting Original
ilyas sahin, MD· @ilyassahinMD · X·· 1 day agoScore70
Body

Two more #ESMO26 papers in @NEJM today:

In EGFR-mutated, MET-altered NSCLC progressing on osimertinib, adding savolitinib improved PFS (HR 0.55) and OS (HR 0.68) vs platinum-pemetrexed. 12-month OS was 70% vs 53%.

In previously treated KRAS G12C-mutated NSCLC, divarasib improved median PFS (9.8 vs 5.7 months; HR 0.58) and OS (17.7 vs 12.0 months; HR 0.56) vs sotorasib or adagrasib.

109 views · 0 likes · 0 reposts · 0 replies

Source: ilyas sahin, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.